Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors

Abstract

Background

Analyses of clinical outcomes following radiotherapy (RT) have advanced our understanding of fundamental radiobiological characteristics in head and neck squamous cell carcinoma (HNSCC). Low fractionation sensitivity appears to be a common feature, as well as susceptibility to changes in overall treatment time (OTT). Large tumors should be harder to cure if a successful RT requires the sterilization of all clonogenic cells. Congruently, primary tumor volume has proven to be an important parameter. However, most findings come from an era when p16-negative HNSCC was the dominant tumor type. HPV-associated, p16-positive, oropharyngeal tumors (OPSCC) are more radiosensitive and have better outcome. The current study aims to investigate the role of primary tumor volume, OTT and estimate α$/\beta$-ratio for p16-positive OPSCC, and to quantify the differences in radiosensitivity depending on p16-status.

Methods

A cohort of 523 patients treated with RT was studied using a tumor control probability (TCP)-model that incorporates primary tumor volume (V) raised to an exponent c, OTT and α$/\beta$-estimation. The significance of V was also investigated in Cox-regression models.

Results

In the p16-positive cohort (n = 433), the volume exponent $c$ was 1.44 (95%CI 1.06–1.91), compared to 0.90 (0.54–1.32) for p16-negative tumors (n = 90). Hazard ratios per tumor volume doubling were 2.37 (1.72–3.28) and 1.83 (1.28–2.62) for p16-positive and p16-negative, respectively. The estimated α$/\beta$-ratio was 9.7 Gy (−2.3–21.6), and a non-significant daily loss of 0.30 Gy (−0.17–0.92) was found. An additional dose of 6.8 Gy (interquartile range 4.8-9.1) may theoretically counteract the more radioresistant behavior of p16-negative tumors.

Conclusion

Primary tumor volume plays a crucial role in predicting local tumor response, particularly in p16-positive OPSCC. The estimated α/β-ratio for p16-positive oropharyngeal tumors aligns with previous HNSCC studies, whereas the impact of prolonged OTT was slightly less than previously reported. The differences in radiosensitivity depending on p16-status were quantified. The findings should be validated in independent cohorts.

Keywords:

• TCP
• tumor volume
• oropharyngeal tumors
• overall treatment time
• fractionation

Acknowledgements

The authors are most grateful for the generous sharing of data from the ARTSCAN trial [22] by Professor Björn Zackrisson, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden, and from the perspective PET-trial [58] by MD PhD Johanna Sjövall, Department of Otorhinolaryngology – Head and Neck Surgery, Skåne University Hospital, Lund University, Lund, Sweden.

Disclosure statement

No potential conflict of interest was reported by the author(s)

Data availibility statement

Research data are not available at this time.

Additional information

Funding

This work was supported by Fru Berta Kamprads Stiftelse